Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 in Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
NCT04868162Phase 2Completed
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in head and neck squamous cell carcinoma (HNSCC), sponsored by Lepu Biopharma Co., Ltd.. Started Apr 2021; status: completed.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04868162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868162.